Adalimumab trough levels of 4.0 mg/L or higher among patients with RA were linked to greater treatment response and achievement of remission.

Adalimumab and secukinumab are the only FDA-approved biologic drugs to treat hidradenitis suppurativa, limiting options for ...

The company will protect the branded anti-interleukin (IL)-12/23 biologic against sales erosion from pending biosimilars.

For patients with psoriatic arthritis, switching directly from adalimumab to tofacitinib with no washout period presents no ...

AbbVie (ABBV) continues to dominate the adalimumab market with 72% share in the U.S., despite biosimilar threats gaining ground. Read more here.

With high biologic treatment failure rates common among patients who have hidradenitis suppurativa (HS), investigators set ...

AbbVie (ABBV) continues to dominate the adalimumab market with 72% share in the U.S., despite biosimilar threats gaining ground. Read more here.

Losing U.S. exclusivity in early 2023, Humira, the top-selling arthritis medication from AbbVie, let biosimilars from Amgen ( ...

Serum level of inflammatory marker C-reactive protein (CRP) predicted response to adalimumab (Humira) treatment for patients ...

The FDA expanded the approval of mirikizumab (Omvoh) to include treatment of adults with moderately to severely active ...

A study of biologic-naive patients with psoriasis or PsA found that IL-17, IL-12/23, and IL-23 inhibitors have cardiovascular ...